Q-omics provides the consensus-scored MIR4453HG profile across patient tissues and cancer cell-line models. MIR4453HG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4453HG is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, MIR4453HG RNA expression shows 20,316 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, THCA, and THYM as cancer lineages where MIR4453HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4453HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4453HG survival associations across molecular data types. MIR4453HG RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4453HG RNA expression–survival associations across cancer types. High MIR4453HG expression shows unfavorable associations in MESO, UVM and LIHC, but favorable associations in UCS, READ and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4453HG RNA expression.
This table summarizes MIR4453HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4453HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4453HG shows lower tumor expression in THCA, KIRC and BRCA and higher tumor expression in LIHC, HNSC and COAD. The THCA box plot shows higher MIR4453HG RNA expression in normal versus tumor tissue (log2 FC = −0.930, t-test p < 0.001).
This table shows molecular features associated with MIR4453HG in patient tissues and cancer cell lines. In patient samples, MIR4453HG shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
